CRISPR Gene-Editing: Moving Outside Our Bodies and Into the World – BU News Service
BU News Service |
CRISPR Gene-Editing: Moving Outside Our Bodies and Into the World
BU News Service Scientists’ ability to edit our genes is increasingly accurate, efficient, and practical. With the development of the CRISPR/Cas9 gene-editing system, researchers … CRISPR Builds More Powerful CAR T CellsOncLive CRISPR Creates More Potent CAR T Cells – Targeted OncologyTargeted Oncology Next Big Future: CRISPR gene therapy is enhancing t-cell …Next Big Future Genetic Literacy Project all 13 news articles » |
|
Hitting Cancer with High-Intensity Ultrasound and Immunotherapy
Newswise (press release) Newswise — In a new study published today in JCI Insight, UC Davis researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates … |
OncLive |
The Potential for Immunotherapy in Pancreatic Cancer
OncLive Panelists: Johanna Bendell, MD, Sarah Cannon Research Institute; Eileen O’Reilly, MD, Memorial Sloan-Kettering Cancer Center; John Marshall, MD, Ruesch Cancer Center at the Lombardi Comprehensive Cancer Center; George Kim, MD, University of … |
Nasdaq |
FDA approves Pfizer, German Merck immunotherapy for skin cancer
Nasdaq It marks the first immunotherapy approval for the collaboration of Pfizer and Germany-based Merck, which has been playing catch-up with rivals, such as Bristol-Myers Squibb Co <BMY.N>, Merck & Co <MRK.N> and Roche Holding AG <ROG.S>. “While skin … |
FiercePharma |
FDA approves Pfizer, German Merck immunotherapy for skin cancer
Reuters It marks the first immunotherapy approval for the collaboration of Pfizer and Germany-based Merck, which has been playing catch-up with rivals, such as Bristol-Myers Squibb Co, Merck & Co and Roche Holding AG . “While skin cancer is one of the most … Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy BavencioFiercePharma FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell …Yahoo Finance Pfizer (PFE) and Merck (MRK) BioPharma Unit Get FDA Approval for BAVENCIO® (Avelumab), the 1st Immunotherapy …StreetInsider.com Medscape –FDA.gov all 20 news articles » |